{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"-4.28","upperLimit":"5.46","value":"0.59"},{"groupId":"OG001","lowerLimit":"-5.14","upperLimit":"3.98","value":"-0.58"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"27"},{"groupId":"OG001","value":"31"}],"units":"Participants"}],"description":"The Cushing QoL patient questionnaire, which evaluates the health-related QoL in patients with Cushing syndrome, comprises 12 questions, each with 5 possible answers. The total score ranges from 12-60, with a higher score indicating improvement in QoL. The Cushing QoL instrument addresses known problem areas associated with Cushing syndrome including trouble sleeping, wound healing/bruising, irritability/mood swings/anger, self-confidence, physical changes, ability to participate in activities, interactions with friends and family, memory issues, and future health concerns.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive the same dose of relacorilant as the last dose administered in the OL Phase.\n\nRelacorilant: Relacorilant is supplied as 100 mg capsules for oral dosing.","id":"OG000","title":"Relacorilant (RW Phase)"},{"description":"Patients who meet any of the response criteria will advance to the RW Phase of the study and receive placebo matched to study drug.\n\nPlacebo: Placebo matched to study drug","id":"OG001","title":"Placebo (RW Phase)"}],"paramType":"LEAST_SQUARES_MEAN","populationDescription":"The analysis population was patients in the ITT-RW Population.","reportingStatus":"POSTED","timeFrame":"Week 22 (end of OL Phase) and Week 36 (Week 12 of RW Phase)","title":"Change in Cushing Quality of Life (QoL) Normalized Total Score During the RW Phase","type":"OTHER_PRE_SPECIFIED","unitOfMeasure":"score on a scale"}